"If one word described the vaccine industry during the last decades of the 20th century, it was "shrinking." The perception of the business as a low-growth, low-margin business, fraught with manufacturing challenges and liability risks as well as the siren song of chronic therapeutics, discouraged new entrants and drove many companies in other directions. Today, the landscape has changed dramatically. Major pharmaceutical companies and startups are jumping back in, driven by scientific advances, demonstrated success with innovative, high-value products and increasing awareness of public health threats such as pandemic influenza. This session will explore some of the exciting areas of vaccine development and what this revitalized public and commercial interest means for global public health."

Objective1:Explore forces driving the re-ignited interest in vaccine development and business.

Objective2:Detail the exciting advancements in vaccine development.

Objective3:Look broadly at how this renewed public/commercial interest will affect global health.